Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 2Recruiting 2Completed 2Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Breast Neoplasms 333Neoplasms 221Prostatic Neoplasms 197Carcinoma, Non-Small-Cell Lung 156Lung Neoplasms 135Pancreatic Neoplasms 118Colorectal Neoplasms 103Neoplasm Metastasis 100Carcinoma, Hepatocellular 96Leukemia, Myeloid, Acute 94Multiple Myeloma 91Brain Neoplasms 89Lymphoma 86Head and Neck Neoplasms 76Melanoma 73Ovarian Neoplasms 72Leukemia 71Leukemia, Lymphocytic, Chronic, B-Cell 69Glioblastoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Colonic Neoplasms 61Recurrence 59Lymphoma, Non-Hodgkin 54Rectal Neoplasms 50Hematologic Neoplasms 50Lymphoma, Follicular 49Glioma 49Squamous Cell Carcinoma of Head and Neck 47Lymphoma, Large B-Cell, Diffuse 47Carcinoma, Renal Cell 47

Interventions

Temozolomide 1Microarray Analysis 1DNA Methylation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Growth Hormone-Secreting Pituitary Adenoma × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡